SA.100: Next-generation targeted antibacterial product entering European market

Project Information

StaphIMPACT

Grant agreement ID: 873591

DOI

10.3030/873591

Project closed

EC signature date 11 September 2019

Start date 1 July 2019

End date 31 December 2021

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 3 978 625,00

EU contribution

€ 2 495 937,50

Coordinated by

MICREOS HUMAN HEALTH BV
Netherlands

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Open Research Data Pilot (1)

Data Management Plan

Websites, patent fillings, videos etc. (3)

Presentation at medical conference
Press releases, promotional and information materials to relevant stakeholders

Press releases promotional and information materials to relevant stakeholders

Full publication submitted to medical journal

Publications

Peer reviewed articles (1)

Topical S. aureus – Targeting Endolysin Significantly Improves Symptoms and QoL in Individuals With Atopic Dermatitis

Author(s): Magali Moreau PhD,a Sophie Seité PhD,b Luc Aguilar PhD,c Olivier Da Cruz MSc,d Julia Puech PharmD,d Johan Frieling MD PhD,e Ann’Laure Demessant PharmDb
Published in: Journal Drugs in Dermatology, Issue 2021;20(12), 2021, Page(s) 1323-1328, ISSN 1545-9616
Publisher: Journal of Drugs in Dermatology, Inc.
DOI: 10.36849/jdd.6363